Address

Deutscher Platz 5b

04103 Leipzig  

Telefon +49 341 697 678 20 

Telefax +49 341 697 678 29 

Short description

WHAT IS ADVERSIS PHARMA GMBH?
Adversis Pharma GmbH is a biotechnology company founded in 2018 and based in the "BioCity" biotech campus in Leipzig. Adversis Pharma sees itself as an innovative service provider for the diagnostics and pharmaceutical industry that orients test developments to the market and its end customers and pursues them with the highest priority. Adversis Pharma is backed by a team of shareholders with many years of experience in the fields of clinical diagnostics, strategic corporate management and international sales and marketing. They are supported by experts in the fields of medicine, regulatory affairs and international relations. This makes Adversis Pharma a competent partner for your questions.

WHAT DOES ADVERSIS PHARMA DO?
Adversis Pharma specialises in biomarker-based diagnostics for tumour diseases, which are often used as companion diagnostics (CDx) in conjunction with therapy, as well as in the direct or indirect detection of pathogens. In the development of diagnostics, almost all molecular biological techniques and biochemical methods are used in order to be able to develop robust and reliable tests. Sales are made directly or through distribution partners worldwide.

BIOMARKER-BASED DIAGNOSTICS
Advances in medicine over the last 20 years have produced a wide range of effective therapeutics to successfully treat patients. With the help of biomarkers, which objectively measure or quantify a biological process, it is now possible to assess the suitability of these therapeutics on an individual basis and to develop a treatment strategy adapted to the patient. Of particular interest to treating physicians are those biomarkers whose presence or absence often coincides with a therapy's success or failure.

COMPANION DIAGNOSTICS
These are diagnostics that have been validated in controlled clinical trials and are critical to the treatment decision with a specific therapeutic agent. Thus, these tests can significantly improve the benefit-risk ratio of treatment. CDx are part of "personalised medicine", which involves the development of therapies that are tailored to patients with specific types of cancer and provide customised treatment approaches.

RESEARCH
Adversis Pharma's research team consists of biochemists, biologists, pharmacists and bioinformaticians who develop therapy-relevant diagnostics in close cooperation with physicians. The team has at its disposal all the relevant procedures (ELISA, qPCR, Next Generation Sequencing) as well as a broad spectrum of methods for successful protein expression and purification.

Contact / Marketing

info@adversis-pharma.de

https://www.adversis-pharma.de